

# Frederick Ofosu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4768070/publications.pdf>

Version: 2024-02-01

35  
papers

1,230  
citations

361296

20  
h-index

414303

32  
g-index

35  
all docs

35  
docs citations

35  
times ranked

555  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. <i>Thrombosis Research</i> , 1986, 43, 491-495.	0.8	139
2	Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. <i>Thrombosis and Haemostasis</i> , 2005, 94, 958-964.	1.8	130
3	Thrombin Regulation in Children Differs from Adults in the Absence and Presence of Heparin. <i>Thrombosis and Haemostasis</i> , 1994, 72, 836-842.	1.8	114
4	The haemorrhagic and antithrombotic effects of dermatan sulphate. <i>British Journal of Haematology</i> , 1986, 64, 309-317.	1.2	87
5	Thrombin and Antithrombotics. <i>Seminars in Thrombosis and Hemostasis</i> , 1998, 24, 87-91.	1.5	66
6	Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. <i>Thrombosis Research</i> , 1988, 52, 517-527.	0.8	63
7	Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth. <i>Thrombosis Research</i> , 1985, 40, 81-89.	0.8	57
8	Pharmacological Actions of Sulodexide. <i>Seminars in Thrombosis and Hemostasis</i> , 1998, 24, 127-138.	1.5	56
9	Factors that contribute to the immunogenicity of therapeutic recombinant human proteins. <i>Thrombosis and Haemostasis</i> , 2008, 99, 874-882.	1.8	52
10	Thrombin Regulation in Mother and Fetus During Pregnancy. <i>Seminars in Thrombosis and Hemostasis</i> , 1992, 18, 81-90.	1.5	48
11	The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III. <i>Thrombosis Research</i> , 1980, 20, 391-403.	0.8	45
12	Rationale Behind the Development of Low Molecular Weight Heparin Derivatives. <i>Seminars in Thrombosis and Hemostasis</i> , 1985, 11, 13-16.	1.5	41
13	Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. <i>Thrombosis Research</i> , 1982, 28, 487-497.	0.8	35
14	Effects of Dermatan Sulfate and Heparin on Inhibition of Thrombus Growth in Vivo. <i>Annals of the New York Academy of Sciences</i> , 1989, 556, 304-312.	1.8	34
15	Prolonged Antithrombin Activity of Low-Molecular-Weight Heparins. <i>Circulation</i> , 1995, 92, 2819-2824.	1.6	32
16	Control Mechanisms in Thrombin Generation. <i>Seminars in Thrombosis and Hemostasis</i> , 1996, 22, 303-308.	1.5	30
17	Activation of factor X and prothrombin in antithrombin-III depleted plasma: The effects of heparin. <i>Thrombosis Research</i> , 1981, 23, 331-345.	0.8	25
18	Heparin Cofactor II and Other Endogenous Factors in the Mediation of the Antithrombotic and Anticoagulant Effects of Heparin and Dermatan Sulfate. <i>Seminars in Thrombosis and Hemostasis</i> , 1985, 11, 133-137.	1.5	25

#	ARTICLE	IF	CITATIONS
19	Mechanisms of Action of Heparin: Applications to the Development of Derivatives of Heparin and Heparinoids with Antithrombotic Properties. <i>Seminars in Thrombosis and Hemostasis</i> , 1988, 14, 9-17.	1.5	21
20	Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography. <i>Thrombosis Research</i> , 1980, 20, 77-83.	0.8	20
21	Hemostatic System Activation in Patients with Lupus Anticoagulant and Essential Thrombocythemia. <i>Seminars in Thrombosis and Hemostasis</i> , 1994, 20, 324-327.	1.5	16
22	Transfusion-Induced Specific Anti-Factor XI Inhibitor in a Patient with Previously Unrecognized Factor XI Deficiency. <i>American Journal of Clinical Pathology</i> , 1988, 89, 418-422.	0.4	15
23	Lack of Relationship Between Enhanced Bleeding Induced by Heparin and Other Sulfated Polysaccharides and Enhanced Catalysis of Thrombin Inhibition. <i>Seminars in Thrombosis and Hemostasis</i> , 1986, 12, 324-327.	1.5	12
24	Effects of heparin fractions of different affinities to antithrombin III and thrombin on the inactivation of thrombin and factor Xa by antithrombin III. <i>Canadian Journal of Biochemistry and Cell Biology</i> , 1984, 62, 975-983.	1.3	11
25	Altered regulation of in-vivo coagulation in orthopedic patients prior to knee or hip replacement surgery. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 219-225.	0.5	11
26	Evolution of Thrombosis. <i>Annals of the New York Academy of Sciences</i> , 1987, 516, 586-604.	1.8	10
27	Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment. <i>Thrombosis and Haemostasis</i> , 2006, 96, 568-577.	1.8	9
28	Anticoagulant Actions of Tissue Factor Pathway Inhibitor on Tissue-Factor-Dependent Plasma Coagulation. <i>Seminars in Thrombosis and Hemostasis</i> , 1995, 21, 240-244.	1.5	8
29	The factor VIII-independent activation of factor X by factors IXa and VII in plasma. <i>Thrombosis Research</i> , 1981, 21, 23-33.	0.8	5
30	Plasmin accelerates platelet-dependent prothrombinase formation without activating the platelets. <i>British Journal of Haematology</i> , 1996, 92, 458-465.	1.2	5
31	Propagating factor IX-producing hepatocytes for haemophilia B therapy. <i>Thrombosis and Haemostasis</i> , 2008, 99, 799-800.	1.8	5
32	Differences in the safety profiles of two low-molecular-weight heparins. <i>Thrombosis and Haemostasis</i> , 2008, 99, 989-990.	1.8	3
33	Current use of biologicals in thrombosis and haemostasis. <i>Thrombosis and Haemostasis</i> , 2008, 99, 805-806.	1.8	0
34	An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes. <i>Thrombosis Research</i> , 2015, 136, 1053-1054.	0.8	0
35	Perspectives on the Role of Platelets in Hemostasis and Thrombosis. , 1984, , 115-126.		0